Fig. 2: Possible role and underlying mechanisms of ARL6IP5 in HCC. | Cancer Gene Therapy

Fig. 2: Possible role and underlying mechanisms of ARL6IP5 in HCC.

From: ARL6IP5 in cancers: bidirectional function and therapeutic value

Fig. 2: Possible role and underlying mechanisms of ARL6IP5 in HCC.

The footnote of Fig. 2: ARL6IP5 inhibits HCC by suppressing MMP-2, FAK, and MAPK signaling pathway. However, ARL6IP5 can promote HCV replication by inhibiting EAAC1, and thus promote HCC. ARL6IP5 also enhances oxidative stress in HCV-infected liver, thereby increasing the risk of HCC. Meanwhile, MAPKs analogs suppress HCC via inhibiting HCV replication.

Back to article page